Patents by Inventor George D. Hartman

George D. Hartman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mitotic kinesin inhibitors
    Patent number: 7732472
    Abstract: The present invention relates to dihydroisoxazoles that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: August 15, 2005
    Date of Patent: June 8, 2010
    Assignees: Merck & Co., Inc., Merck Sharp & Dohme Corp.
    Inventors: Mark E. Fraley, Robert M. Garbaccio, George D. Hartman
  • Prodrugs of mitotic kinesin inhibitors
    Patent number: 7718687
    Abstract: The present invention relates to prodrugs of dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: June 27, 2005
    Date of Patent: May 18, 2010
    Assignee: Merck Sharp & Dohme Corp.,
    Inventors: Paul J. Coleman, Christopher D. Cox, George D. Hartman
  • Mitotic kinesin inhibitors
    Patent number: 7632833
    Abstract: The present invention relates to tricyclic pyrazoles according to Formula (I) that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: June 27, 2005
    Date of Patent: December 15, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Jeffrey M. Bergman, Paul J. Coleman, Mark E. Fraley, Robert M. Garbaccio, George D. Hartman, Chunze Li, Lou Anne Neilson, Christy M. Olson, Edward S. Tasber
  • Mitotic kinesin inhibitors
    Patent number: 7632839
    Abstract: The present invention relates to fluorinated aminoalkyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine derivatives that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: January 13, 2006
    Date of Patent: December 15, 2009
    Assignee: Merck & Co. Inc.
    Inventors: Paul J. Coleman, George D. Hartman
  • Mitotic kinesin inhibitors
    Patent number: 7625912
    Abstract: The present invention relates to 2-phenylpyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: December 1, 2009
    Assignee: Merck & Co. Inc
    Inventors: Kenneth L. Arrington, Mark E. Fraley, George D. Hartman
  • Mitotic kinesin inhibitors
    Patent number: 7625936
    Abstract: The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: December 1, 2009
    Assignee: Merck & Co. Inc.
    Inventors: Paul J. Coleman, Christopher D. Cox, George D. Hartman
  • Mitotic kinesin inhibitors
    Patent number: 7618971
    Abstract: The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: June 27, 2005
    Date of Patent: November 17, 2009
    Assignee: Merck & Co. Inc.
    Inventors: Paul J. Coleman, Christopher D. Cox, Mark E. Fraley, George D. Hartman, John Schreier
  • Inhibitors of Checkpoint Kinases
    Publication number: 20090258852
    Abstract: The instant invention provides for compounds which comprise benzoisoquinolinones and aza derivatives that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.
    Type: Application
    Filed: June 30, 2006
    Publication date: October 15, 2009
    Inventors: Kenneth L. Arrington, Vadim Y. Dudkin, Mark E. Fraley, Robert M. Garbaccio, George D. Hartman, Shaei Y. Huang, Constantine Kreatsoulas, Edward S. Tasber
  • Mitotic kinesin inhibitors
    Patent number: 7553838
    Abstract: The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: June 27, 2005
    Date of Patent: June 30, 2009
    Assignee: Merck & Co. Inc.
    Inventors: Mark E. Fraley, George D. Hartman
  • Mitotic Kinesin Inhibitors
    Publication number: 20090124641
    Abstract: The present invention relates to fluorinated 2-aminomethylquinazolinone derivatives that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: January 13, 2006
    Publication date: May 14, 2009
    Inventors: Paul J. Coleman, George D. Hartman
  • Proline bis-amide orexin receptor antagonists
    Publication number: 20090118200
    Abstract: The present invention is directed to proline bis-amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: May 22, 2006
    Publication date: May 7, 2009
    Inventors: Jeffrey M. Bergman, Paul J. Coleman, Christopher D. Cox, George D. Hartman, Craig Lindsley, Swati Pal Mercer, Anthony J. Roecker, David B. Whitman
  • Mitotic Kinesin Inhibitors
    Publication number: 20090005418
    Abstract: The present invention relates to dihydroisoxazoles that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: August 15, 2005
    Publication date: January 1, 2009
    Applicant: MERCK & CO., INC.
    Inventors: Mark E. Fraley, Robert M. Garbaccio, George D. Hartman
  • Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP
    Patent number: 7465746
    Abstract: The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention is also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: December 16, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Paul J. Coleman, Christopher D. Cox, Robert M. Garbaccio, George D. Hartman
  • Mitotic Kinesin Inhibitors
    Publication number: 20080287414
    Abstract: The present invention relates to tricyclic pyrazoles according to Formula (I) that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: June 27, 2005
    Publication date: November 20, 2008
    Applicant: MERCK & CO., INC.
    Inventors: Jeffrey M. Bergman, Paul J. Coleman, Mark E. Fraley, Robert M. Garbaccio, George D. Hartman, Chunze Li, Lou Anne Neilson, Christy M. Olson, Edward S. Tasber
  • Tyrosine kinase inhibitors
    Publication number: 20080274107
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: April 21, 2008
    Publication date: November 6, 2008
    Inventors: Mark E. Fraley, Kenneth L. Arrington, Mark T. Bilodeau, George D. Hartman, William F. Hoffman, Yuntae Kim, Randall W. Hungate
  • Mitotic Kinesin Inhibitors
    Publication number: 20080207693
    Abstract: The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: March 10, 2006
    Publication date: August 28, 2008
    Inventors: Paul J. Coleman, Christopher D. Cox, George D. Hartman
  • Mitotic Kinesin Inhibitors
    Publication number: 20080194582
    Abstract: The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: March 10, 2006
    Publication date: August 14, 2008
    Inventors: Paul J. Coleman, Christopher D. Cox, George D. Hartman
  • Mitotic Kinesin Inhibitors
    Publication number: 20080139586
    Abstract: The present invention relates to fluorinated aminoalkyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine derivatives that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: January 13, 2006
    Publication date: June 12, 2008
    Inventors: Paul J. Coleman, George D. Hartman
  • Substituted thienopyrimidinones as a mitotic kinesin inhibitor
    Patent number: 7378411
    Abstract: The present invention relates to thienopyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: December 2, 2002
    Date of Patent: May 27, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, George D. Hartman, William F. Hoffman
  • Mitotic Kinesin Inhibitors
    Publication number: 20080102068
    Abstract: The present invention relates to fluorinated 2-aminomethylthienopyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: January 13, 2006
    Publication date: May 1, 2008
    Inventors: Paul J. Coleman, George D. Hartman